Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Apr-2017
No. of pages: 248
Inquire Before Buying

Summary

The Global Companion Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Companion Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in companion diagnostics partnering deals

Companion diagnostics partnering agreement structure

Companion diagnostics partnering contract documents

Top companion diagnostics deals by value

Most active companion diagnostics dealmakers

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

Key benefits

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Companion Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies

Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies

Identify most active Companion Diagnostics dealmakers since 2010

Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.

Companion Diagnostics Partnering Terms and Agreements includes:

Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Companion Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Companion Diagnostics deals

Access to Companion Diagnostics contract documents

Leading Companion Diagnostics deals by value since 2010

Most active Companion Diagnostics dealmakers since 2010

In Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 350 Companion Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Companion Diagnostics dealmaking

2.1. Introduction
2.2. Companion Diagnostics partnering over the years
2.3. Most active Companion Diagnostics dealmakers
2.4. Companion Diagnostics partnering by deal type
2.5. Companion Diagnostics partnering by therapy area
2.6. Deal terms for Companion Diagnostics partnering
2.6.1 Companion Diagnostics partnering headline values
2.6.2 Companion Diagnostics deal upfront payments7
2.6.3 Companion Diagnostics deal milestone payments
2.6.4 Companion Diagnostics royalty rates

Chapter 3 - Leading Companion Diagnostics deals

3.1. Introduction
3.2. Top Companion Diagnostics deals by value

Chapter 4 - Most active Companion Diagnostics dealmakers

4.1. Introduction
4.2. Most active Companion Diagnostics dealmakers
4.3. Most active Companion Diagnostics partnering company profiles

Chapter 5 - Companion Diagnostics contracts dealmaking directory

5.1. Introduction
5.2. Companion Diagnostics contracts dealmaking directory

Chapter 6 - Companion Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Companion Diagnostics deals by company A-Z

Appendix 2 - Companion Diagnostics deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Companion Diagnostics deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Companion Diagnostics deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Companion Diagnostics partnering since 2010
Figure 2: Active Companion Diagnostics dealmaking activity since 2010
Figure 3: Companion Diagnostics partnering by deal type since 2010
Figure 4: Companion Diagnostics partnering by disease type since 2010
Figure 5: Companion Diagnostics deals with a headline value
Figure 6: Companion Diagnostics deals with an upfront value
Figure 7: Companion Diagnostics deals with a milestone value
Figure 8: Companion Diagnostics deals with a royalty rate value
Figure 9: Top Companion Diagnostics deals by value since 2010
Figure 10: Most active Companion Diagnostics dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • United States Enzyme-Linked Immunosorbent Assay (ELISA) Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 19-Jul-2017        Price: US 4480 Onwards        Pages: 123
    Enzyme-linked immunosorbent assay (ELISA), also known as an enzyme immunoassay (EIA), is a biochemical technique used mainly in immunology to detect the presence of an antibody or an antigen in a sample. The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries,such as ELISA application in food industry.Scope of the Report:This report focuses on the Enzyme-Linked Immunosorbent Assay (ELISA) in Uni......
  • Europe Enzyme-Linked Immunosorbent Assay (ELISA) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 123
    Enzyme-linked immunosorbent assay (ELISA), also known as an enzyme immunoassay (EIA), is a biochemical technique used mainly in immunology to detect the presence of an antibody or an antigen in a sample. The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries,such as ELISA application in food industry. Scope of the Report: This report focuses on the Enzyme-Linked Immunosorbent Assay (ELISA) in Eu......
  • 2017 Top 5 Enzyme-Linked Immunosorbent Assay (ELISA) Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 14-Jun-2017        Price: US 4960 Onwards        Pages: 156
    "This report will be delivered in 2-3 business days after the order is placed." The Global Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Enzyme-Linked Immunosorbent Assay (ELISA) in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuse......
  • 2017-2022 China Enzyme-Linked Immunosorbent Assay (ELISA) Market Report (Status and Outlook)
    Published: 14-Jun-2017        Price: US 3360 Onwards        Pages: 110
    "This report will be delivered in 2-3 business days after the order is placed." The Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include - R&D Systems - Thermo Fisher Scientific - Ortho Clinical Diagnostics - BD Biosciences - ZEUS Scie......
  • 2017-2022 Global Top Countries Enzyme-Linked Immunosorbent Assay (ELISA) Market Report
    Published: 14-Jun-2017        Price: US 4960 Onwards        Pages: 156
    "This report will be delivered in 2-3 business days after the order is placed." The Global Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Enzyme-Linked Immunosorbent Assay (ELISA) in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, I......
  • 2017-2022 India Enzyme-Linked Immunosorbent Assay (ELISA) Market Report (Status and Outlook)
    Published: 14-Jun-2017        Price: US 3360 Onwards        Pages: 110
    "This report will be delivered in 2-3 business days after the order is placed." The Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include - R&D Systems - Thermo Fisher Scientific - Ortho Clinical Diagnostics - BD Biosciences - ZEUS Scie......
  • 2017-2022 Japan Enzyme-Linked Immunosorbent Assay (ELISA) Market Report (Status and Outlook)
    Published: 14-Jun-2017        Price: US 3360 Onwards        Pages: 110
    "This report will be delivered in 2-3 business days after the order is placed." The Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include - R&D Systems - Thermo Fisher Scientific - Ortho Clinical Diagnostics - BD Biosciences - ZEUS Scie......
  • 2017-2022 Malaysia Enzyme-Linked Immunosorbent Assay (ELISA) Market Report (Status and Outlook)
    Published: 14-Jun-2017        Price: US 3360 Onwards        Pages: 110
    "This report will be delivered in 2-3 business days after the order is placed." The Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Malaysia market, the top players include - R&D Systems - Thermo Fisher Scientific - Ortho Clinical Diagnostics - BD Biosciences - ZEU......
  • 2017-2022 Philippines Enzyme-Linked Immunosorbent Assay (ELISA) Market Report (Status and Outlook)
    Published: 14-Jun-2017        Price: US 3360 Onwards        Pages: 110
    "This report will be delivered in 2-3 business days after the order is placed." The Enzyme-Linked Immunosorbent Assay (ELISA) market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top players include - R&D Systems - Thermo Fisher Scientific - Ortho Clinical Diagnostics - BD Biosciences ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs